Array Biopharma Inc.

Ventirx Pharmaceuticals, Inc.

Hong-Woon Yang

Jeongbeob Seo

Joseph P Lyssikatos

Steven Wade Andrews

Yutong Jiang

Julia Haas

Qian Zhao

Gabrielle R Kolakowski

Kevin Ronald Condroski

James F Blake

Eli M Wallace

Laurence Edward Burgess

Allison L Marlow

Brad Newhouse

Robert Hershberg

Gregory Dietsch

James Jeffry Howbert

Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, R, R, R, R, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases. 

Macrocyclic compounds as TRK kinase inhibitors

Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R, R, R, R, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases. 

Macrocyclic compounds as Trk kinase inhibitors

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.

Substituted benzoazepines as toll-like receptor modulators

Macrocyclic compounds as trk kinase inhibitors

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

Disclosed are compounds of the Formulas III and IV and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, R, and Rare as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Heterocyclic inhibitors of MEK and methods of use thereof

Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, R, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Disclosed are compounds of the Formula and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, R, R, W, and X are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Heterocyclic inhibitors of MEK and methods of use

Disclosed are compounds of the Formulas I and V and pharmaceutically acceptable salts and prodrugs thereof, wherein R, R, R, Rand R, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Growing community of inventors

Boulder, CO, United States of America

Hong-Woon Yang